Management of Persistent Nausea in Patients with Chronic Kidney Disease

Nausea is one of the most common adverse effects of GLP-1 receptor agonists, occurring in 30-45% of treated patients, according to the American Diabetes Association 1
In patients with moderate-to-severe CKD, GLP-1 receptor agonists cause nausea and vomiting in 15-20% of cases, as reported by the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines 2
These gastrointestinal symptoms typically occur in the initial stage of treatment and gradually diminish as treatment time increases, as stated by the European Association for the Study of Diabetes (EASD) 3
Lisinopril-HCTZ rarely causes isolated nausea without other symptoms, according to the American Heart Association (AHA) 4

Critical Differential Diagnoses to Exclude

Clinical symptoms suggesting gastroparesis include nausea, vomiting, and postprandial abdominal fullness, as defined by the American Gastroenterological Association (AGA) 5
Diabetic gastroparesis occurs in 20-40% of patients with diabetes mellitus, primarily those with long duration of type 1 diabetes with other complications, as reported by the American Diabetes Association (ADA) 5
Advanced CKD can cause nausea through metabolic abnormalities and uremic toxins, according to the National Kidney Foundation (NKF) 4

Obtain complete blood count, serum electrolytes, glucose, liver function tests, lipase, and urinalysis to exclude metabolic causes and assess for dehydration, as recommended by the American College of Physicians (ACP) 6
Check for hypercalcemia, hypothyroidism, and Addison's disease if clinically indicated, according to the Endocrine Society (ES) 6
Assess current renal function (eGFR and creatinine) and compare to baseline, as stated by the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines 6

Assess for dehydration and correct fluid/electrolyte imbalances, which is crucial given the patient's CKD, as recommended by the American Heart Association (AHA) 7
Ensure adequate fluid intake of at least 1.5 L/day, according to the European Society of Cardiology (ESC) 8
Start with dopamine receptor antagonists (metoclopramide 5-10 mg PO three times daily before meals) as first-line therapy, which also promotes gastric emptying if gastroparesis is present, as recommended by the American Gastroenterological Association (AGA) 7, 8
Monitor for extrapyramidal side effects, particularly in elderly patients, as warned by the American Geriatrics Society (AGS) 7, 8

Despite nausea, GLP-1 receptor agonists with proven cardiovascular benefit (including tirzepatide) are recommended for patients with T2D and CKD who do not meet glycemic targets, as stated by the American Diabetes Association (ADA) and the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines 2, 4
GLP-1 receptor agonists reduce albuminuria, slow eGFR decline, and reduce risk of major adverse cardiovascular events, according to the American Heart Association (AHA) and the European Society of Cardiology (ESC) 2
The cardiovascular and renal benefits may outweigh the gastrointestinal side effects, particularly if symptoms can be managed with antiemetics, as recommended by the American College of Cardiology (ACC) and the American Heart Association (AHA) 2, 4